AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18573809 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation treatment through a face mask
Number of subjects: 172
Study 18573809 — intervention group
Group type: COMPARATOR
Intervention: Other interventions (Control)
Number of subjects: 172
Study 16720496 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytostatic drug treatment close to surgery
Number of subjects: 54
Study 16720496 — intervention group
Group type: COMPARATOR
Intervention: Control group (neurologically impaired children)
Number of subjects: 54
Study 15587929 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin (TEI) administered with three 10 mg/kg Q12h loading infusions, and maintenance with 10 mg/kg or 15 mg/kg Q24h
Number of subjects: 20
Study 11412732 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradural-epidural analgesia (IEA) - 25 microgram of intradural fentanyl with 2.5 mg of isobaric bupivacaine with adrenalin, followed by 8 mL bolus of 0.125% bupivacaine at 8 ml/h
Number of subjects: 42
Study 11412732 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural analgesia (CEA) - 8 ml of 0.25% bupivacaine with adrenalin, followed by perfusion of 0.125% bupivacaine and 1 microgram/ml of fentanyl at 8 ml/h
Number of subjects: 42
Study 9407424 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril
Number of subjects: 583
Study 9407424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 583
Study 7705386 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg 17 beta-oestradiol
Number of subjects: 23
Study 7705386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 2651054 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic magnesium supplementation (2 g/day)
Number of subjects: 8
Study 920124 — intervention group
Group type: EXPERIMENTAL
Intervention: Transverse technique (47 cases)
Number of subjects: 88
Study 920124 — intervention group
Group type: COMPARATOR
Intervention: Sagittal technique (41 cases)
Number of subjects: 88
Study 920124 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 88
Study 31567305 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling and auricular acupressure
Number of subjects: 109
Study 31567305 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling and placebo acupressure
Number of subjects: 109
Study 31567305 — intervention group
Group type: COMPARATOR
Intervention: Self-help for smoking cessation (control)
Number of subjects: 109
Study 31567305 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 109
Study 31331968 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalfampridine 10 mg twice daily for 12 weeks
Number of subjects: 120
Study 31331968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 28143388 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac telerehabilitation using a patient-centred web application
Number of subjects: 300
Study 28143388 — intervention group
Group type: COMPARATOR
Intervention: Centre-based cardiac rehabilitation
Number of subjects: 300
Study 28143388 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac telerehabilitation
Number of subjects: 300
Study 23774117 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-remifentanil (PR)
Number of subjects: 66
Study 23774117 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane-sufentanil (SS)
Number of subjects: 66
Study 22280901 — intervention group
Group type: EXPERIMENTAL
Intervention: Aged garlic extract (2.56 g/d)
Number of subjects: 120
Study 20374102 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment based on TCM pattern diagnosis
Number of subjects: 16
Study 20374102 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 16
Study 18471327 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg
Number of subjects: 50
Study 18471327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 15767619 — intervention group
Group type: COMPARATOR
Intervention: L-thyroxine, 100 microg/d (standard treatment)
Number of subjects: 28
Study 15767619 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxine, 75 microg/d plus liothyronine, 5 microg/d (combination treatment)
Number of subjects: 28
Study 15767619 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxine, 87.5 microg/d plus liothyronine, 7.5 microg/d (add-on combination treatment)
Number of subjects: 28
Study 15767619 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient preference
Number of subjects: 28
Study 12627307 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal aerobic exercise
Number of subjects: 24
Study 12627307 — intervention group
Group type: COMPARATOR
Intervention: Resting FBF
Number of subjects: 24
Study 10570752 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-3 (rhIL-3) administered subcutaneously at a dose of 5 micrograms/kg once a day for 10 days starting from day 4 of chemotherapy
Number of subjects: 0
Study 10570752 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-3 (rhIL-3) administered subcutaneously at a dose of 10 micrograms/kg once a day for 10 days starting from day 4 of chemotherapy
Number of subjects: 0
Study 10570752 — intervention group
Group type: COMPARATOR
Intervention: Control observation period (no rhIL-3 administration)
Number of subjects: 0
Study 7818124 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg/kg
Number of subjects: 50
Study 7818124 — intervention group
Group type: COMPARATOR
Intervention: Atracurium 0.3 mg/kg
Number of subjects: 50
Study 2370107 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugates composed of Streptococcus pneumoniae type 12F polysaccharide covalently coupled to diphtheria toxoid
Number of subjects: 0
Study 2370107 — intervention group
Group type: COMPARATOR
Intervention: Pnu-Imune (23-valent pneumococcus vaccine)
Number of subjects: 0
Study 517882 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta-9-tetrahydrocannabinol (THC), 15 mg orally three times a day
Number of subjects: 116
Study 517882 — intervention group
Group type: COMPARATOR
Intervention: Prochlorperazine, 10 mg orally three times a day
Number of subjects: 116
Study 517882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 29882038 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive health guidance focusing on eating quickly
Number of subjects: 141
Study 29882038 — intervention group
Group type: COMPARATOR
Intervention: Standard health guidance about MetS
Number of subjects: 141
Study 31535520 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (group A, n=61)
Number of subjects: 122
Study 31535520 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group B, n=61)
Number of subjects: 122
Study 29806390 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid prototyping (RP) technology for nasoalveolar molding (NAM) appliances
Number of subjects: 39
Study 29806390 — intervention group
Group type: COMPARATOR
Intervention: Traditional NAM protocol
Number of subjects: 39
Study 29806390 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (test and control)
Number of subjects: 39
Study 25714798 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine (PPV23)
Number of subjects: 1200
Study 25714798 — intervention group
Group type: COMPARATOR
Intervention: Control PPV23
Number of subjects: 1200
Study 23474309 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified diet
Number of subjects: 597
Study 23474309 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-feeding duration
Number of subjects: 597
Study 23474309 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-feeding duration adjustment
Number of subjects: 597
Study 21863031 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening every year
Number of subjects: 0
Study 21863031 — intervention group
Group type: COMPARATOR
Intervention: Screening every 3 years
Number of subjects: 0
Study 19811593 — intervention group
Group type: EXPERIMENTAL
Intervention: Academic detailing plus postal prescribing feedback (AD)
Number of subjects: 98
Study 19811593 — intervention group
Group type: COMPARATOR
Intervention: Postal prescribing feedback (PB)
Number of subjects: 98
Study 19811593 — intervention group
Group type: COMPARATOR
Intervention: Cost-effectiveness of postal prescribing feedback service
Number of subjects: 98
Study 19811593 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of prescriber adviser service
Number of subjects: 98
Study 16758905 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial lysate [see text]PC‐19
Number of subjects: 0
Study 15276139 — intervention group
Group type: EXPERIMENTAL
Intervention: QEEG analysis
Number of subjects: 35
Study 11716835 — intervention group
Group type: EXPERIMENTAL
Intervention: English-speaking children
Number of subjects: 0
Study 11716835 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese-speaking children
Number of subjects: 0
Study 9156374 — intervention group
Group type: COMPARATOR
Intervention: Dichloroacetate (50 mg/kg) administered via 30-minute intravenous infusion
Number of subjects: 111
Study 8395087 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy (1.3 Gy twice daily for five weeks, total dose 65 Gy)
Number of subjects: 68
Study 8395087 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (2.0 Gy daily for six weeks, total dose 60 Gy)
Number of subjects: 68
Study 8395087 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy
Number of subjects: 68
Study 8395087 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 68
Study 2441166 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal clonidine patches (2.5 mg)
Number of subjects: 35
Study 2441166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 28927484 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based Behavioral Health Laboratory (BHL) assessment
Number of subjects: 108
Study 28927484 — intervention group
Group type: COMPARATOR
Intervention: In-person Behavioral Health Laboratory (BHL) assessment
Number of subjects: 108
Study 27447693 — intervention group
Group type: EXPERIMENTAL
Intervention: Student-only intervention
Number of subjects: 2801
Study 27447693 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined student-parent intervention
Number of subjects: 2801
Study 27447693 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2801
Study 27447693 — intervention group
Group type: EXPERIMENTAL
Intervention: Student-parent intervention
Number of subjects: 2801
Study 23677620 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D‐PCASL
Number of subjects: 30
Study 23677620 — intervention group
Group type: COMPARATOR
Intervention: SE‐DSC
Number of subjects: 30
Study 23677620 — intervention group
Group type: COMPARATOR
Intervention: GE‐DSC
Number of subjects: 30
Study 22638779 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 178
Study 22638779 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 178
Study 20823351 — intervention group
Group type: EXPERIMENTAL
Intervention: Labeling message
Number of subjects: 97
Study 20823351 — intervention group
Group type: COMPARATOR
Intervention: Generic (no label) message
Number of subjects: 97
Study 19082319 — intervention group
Group type: EXPERIMENTAL
Intervention: No Touch (NT) technique
Number of subjects: 20
Study 19082319 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 20
Study 16170291 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical treatment with DRNA 5 mg vaginal suppositories for 15 days monthly, reduced gradually thereafter
Number of subjects: 220
Study 16170291 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 220
Study 12511763 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical models to predict stroke outcomes
Number of subjects: 2955
Study 10988188 — intervention group
Group type: EXPERIMENTAL
Intervention: LABD plus exercise
Number of subjects: 30
Study 10988188 — intervention group
Group type: EXPERIMENTAL
Intervention: LABD plus exercise plus IMT
Number of subjects: 30
Study 10988188 — intervention group
Group type: EXPERIMENTAL
Intervention: LABD
Number of subjects: 30
Study 8772549 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (250 mg orally at -270 min and 250 mg at -60 min)
Number of subjects: 6
Study 8772549 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox with Pyridostigmine (120 mg orally at -60 min)
Number of subjects: 6
Study 8772549 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox with GHRH (1 microgram/kg, iv at 0 min)
Number of subjects: 6
Study 8772549 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox with GHRP-6 (1 microgram/kg, iv at 0 min)
Number of subjects: 6
Study 8772549 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox with GHRH plus GHRP-6
Number of subjects: 6
Study 8772549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 1728249 — intervention group
Group type: EXPERIMENTAL
Intervention: m-chlorophenylpiperazine (m-CPP; 0.5 mg/kg orally)
Number of subjects: 30
Study 1728249 — intervention group
Group type: EXPERIMENTAL
Intervention: fenfluramine hydrochloride (60 mg orally)
Number of subjects: 30
Study 1728249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 1728249 — intervention group
Group type: EXPERIMENTAL
Intervention: m-chlorophenylpiperazine (m-CPP)
Number of subjects: 30
Study 1728249 — intervention group
Group type: EXPERIMENTAL
Intervention: fenfluramine
Number of subjects: 30
Study 1728249 — intervention group
Group type: EXPERIMENTAL
Intervention: m-chlorophenylpiperazine (m-CPP) and fenfluramine
Number of subjects: 30
Study 6372935 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative percutaneous transhepatic biliary drainage (PTBD) followed by laparotomy
Number of subjects: 65
Study 6372935 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 65
Study 6372935 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative PTBD
Number of subjects: 65
Study 30653344 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell-seeded scaffold
Number of subjects: 33
Study 30653344 — intervention group
Group type: COMPARATOR
Intervention: Scaffold alone
Number of subjects: 33
Study 30431004 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 15 mg daily for 1 week (n = 93)
Number of subjects: 202
Study 30431004 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 15 mg daily for 2 weeks (n = 109)
Number of subjects: 202
Study 27281490 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg for 14 days
Number of subjects: 40
Study 27281490 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 14 days
Number of subjects: 40
Study 24245778 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention measurement condition (participants reported their intentions to eat healthy foods)
Number of subjects: 151
Study 24245778 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (two control groups)
Number of subjects: 151
Study 22226937 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking while texting on a cell phone
Number of subjects: 33
Study 22226937 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking while talking on a cell phone
Number of subjects: 33
Study 22226937 — intervention group
Group type: COMPARATOR
Intervention: Walking without cell phone use (baseline)
Number of subjects: 33
Study 19616880 — intervention group
Group type: EXPERIMENTAL
Intervention: Explosive anger episodes (defined as one attack of explosive anger a month)
Number of subjects: 1544
Study 19616880 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of trauma exposure
Number of subjects: 1544
Study 19616880 — intervention group
Group type: EXPERIMENTAL
Intervention: Latent class analysis
Number of subjects: 1544
Study 19616880 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-traumatic stress and general psychological distress
Number of subjects: 1544
Study 17614750 — intervention group
Group type: EXPERIMENTAL
Intervention: Atosiban
Number of subjects: 585
Study 17614750 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 585
Study 15357156 — intervention group
Group type: EXPERIMENTAL
Intervention: IV administration set changed on day 4 (n = 203)
Number of subjects: 251
Study 15357156 — intervention group
Group type: COMPARATOR
Intervention: IV administration set not changed (n = 201)
Number of subjects: 251
Study 11394609 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior cruciate ligament-reconstructed knee
Number of subjects: 25
Study 11394609 — intervention group
Group type: COMPARATOR
Intervention: Uninjured knee
Number of subjects: 25
Study 11394609 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 uninjured age- and activity-matched subjects)
Number of subjects: 25
Study 11394609 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients (ACL-reconstructed)
Number of subjects: 25
Study 9727728 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI (paroxetine) + augmenting agent (pindolol)
Number of subjects: 80
Study 9727728 — intervention group
Group type: COMPARATOR
Intervention: SSRI (paroxetine) alone
Number of subjects: 80
Study 8053578 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril continued until the morning of surgery
Number of subjects: 51
Study 8053578 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril continued until the morning of surgery
Number of subjects: 51
Study 8053578 — intervention group
Group type: COMPARATOR
Intervention: ACEI therapy stopped the evening before surgery (either enalapril or captopril)
Number of subjects: 51
Study 3197373 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline infusion (0.27 nmol (50 ng) min‐1 kg‐1)
Number of subjects: 7
Study 3197373 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline infusion
Number of subjects: 7
Study 3197373 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (154 mmol/l NaCl)
Number of subjects: 7
Study 29174062 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 5 μg
Number of subjects: 2912
Study 29174062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2912
Study 25780259 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help autogenic relaxation CD, five times a week for at least one month
Number of subjects: 21
Study 25780259 — intervention group
Group type: COMPARATOR
Intervention: Control group (no relaxation training)
Number of subjects: 21
Study 26323043 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic supportive-expressive psychotherapy
Number of subjects: 149
Study 26323043 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medication with clinical management
Number of subjects: 149
Study 26323043 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo with clinical management
Number of subjects: 149
Study 23599435 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg tabalumab
Number of subjects: 158
Study 23599435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 23599435 — intervention group
Group type: EXPERIMENTAL
Intervention: Tabalumab
Number of subjects: 158
Study 20533022 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen plus CPAP
Number of subjects: 40
Study 20533022 — intervention group
Group type: COMPARATOR
Intervention: Oxygen
Number of subjects: 40
Study 18665938 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin 1000 mg with clarithromycin 500 mg and omeprazole 20 mg twice daily for 2 weeks (BID group, n = 93)
Number of subjects: 186
Study 18665938 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin 500 mg four times daily with clarithromycin 500 mg and omeprazole 20 mg twice daily for 2 weeks (QID group, n = 93)
Number of subjects: 186
Study 15962678 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloids (Haemaccel) 10 ml/Kg before positioning
Number of subjects: 20
Study 15962678 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid as maintenance and deposit replacement
Number of subjects: 20
Study 12614558 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic laser (670 nm, 20 mW, frequencies 10 Hz, 25 Hz, 50 Hz) at an energy density of 2 J/cm²
Number of subjects: 2436
Study 12614558 — intervention group
Group type: EXPERIMENTAL
Intervention: Polarized light (400‐2,000 nm, 20 mW, frequency 100 Hz) at an energy density of 5 J/cm²
Number of subjects: 2436
Study 10501745 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of nitric oxide (INO) at 1-40 ppm for up to 30 days or until an endpoint was reached.
Number of subjects: 268
Study 10501745 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment with inhaled nitric oxide (INO)
Number of subjects: 268
Study 10501745 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of nitric oxide (INO)
Number of subjects: 268
Study 10501745 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment without inhaled nitric oxide (INO)
Number of subjects: 268
Study 8951777 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/day aspirin
Number of subjects: 112
Study 8951777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 1755551 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortronic AMP 770 monitor
Number of subjects: 9
Study 1755551 — intervention group
Group type: COMPARATOR
Intervention: Traditional oscillometer (Physiogard SM 785 NI, Odam)
Number of subjects: 9
Study 7074822 — intervention group
Group type: EXPERIMENTAL
Intervention: Propylene and polyethylene glycol
Number of subjects: 18
Study 7074822 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 18
Study 7074822 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (propylene and polyethylene glycol, saline)
Number of subjects: 18
Study 30642973 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster care placement
Number of subjects: 0
Study 30642973 — intervention group
Group type: COMPARATOR
Intervention: Never-institutionalized children
Number of subjects: 0
Study 30642973 — intervention group
Group type: EXPERIMENTAL
Intervention: Ever-institutionalized children
Number of subjects: 0
Study 30642973 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher resting EEG alpha power at age 8
Number of subjects: 0
Study 28663405 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-operative management (n = 8)
Number of subjects: 19